Biovica Eyes 2020 Commercial Launch for DiviTum Metastatic Breast Cancer Assay

Nov 09, 2017

Premium

NEW YORK (360Dx) – Biovica, a Swedish biotechnology company, aims to launch an assay for predicting and monitoring treatment response in cancer patients by 2020.

CEO Anders Rylander said the company will initially market its DiviTum assay for use in breast cancer, though it could be used to monitor cell proliferation in all cancer types. Biovica will seek regulatory clearance for its test in the US as well as in Europe, and is currently engaged in nearly a dozen studies aimed at assessing the test's performance in both regions, he said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

Featured White Papers

Sampling for Optimal cfDNA Extraction

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec

04

Featured Webinar

Clinical-Grade Exome Analysis for Complex and Unsolved Case Investigations

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec

06

Featured Webinar

Mapping The Disease-Variant Landscape To Accelerate Precision Drug Development

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.

Main menu